Edition:
United States

Vermillion Inc (VRML.OQ)

VRML.OQ on NASDAQ Stock Exchange Capital Market

1.26USD
13 Jan 2017
Change (% chg)

-- (--)
Prev Close
$1.26
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
8,768
52-wk High
$1.85
52-wk Low
$0.76

VRML.OQ

Chart for VRML.OQ

About

Vermillion, Inc. is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician's... (more)

Overall

Beta: 1.74
Market Cap(Mil.): $65.86
Shares Outstanding(Mil.): 52.27
Dividend: --
Yield (%): --

Financials

  VRML.OQ Industry Sector
P/E (TTM): -- 46.47 30.92
EPS (TTM): -0.33 -- --
ROI: -113.17 -0.87 14.82
ROE: -120.43 -0.56 16.24

BRIEF-Vermillion announces reimbursement code updates for Overa and OVA1

* Vermillion Inc - Co and unit Aspira Labs, have received a proprietary laboratory analyses (PLA) code (0003U) for Overa (MIA2G) Source text for Eikon: Further company coverage:

Jan 09 2017

BRIEF-Vermillion Q3 revenue $623,000

* Vermillion Inc - expect net cash utilization to be less than $3.0 million in Q4 of 2016

Nov 10 2016

BRIEF-Vermillion reports Q2 loss per share $0.07

* Q2 revenue $709,000 versus $535,000 Source text for Eikon: Further company coverage:

Aug 10 2016

Competitors

  Price Chg
Abbott Laboratories (ABT.N) $40.93 +0.21
Becton Dickinson and Co (BDX.N) $173.35 -0.14
Arrayit Corp (ARYC.PK) $0.01 +0.00

Earnings vs. Estimates